Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2024—Bio-Rad Laboratories announced it received My Green Lab certification for its R&D facilities in Irvine, Calif. It has been certified at My Green Lab’s highest rating, green, which reflects the percentage of possible green lab best practices that have been adopted and the extent to which they have been adopted by the lab.
April 2024—Recordati Rare Diseases has introduced its new educational website, thinkimcd.us. The platform is tailored for pathologists, offering comprehensive support for the diagnostic process of idiopathic multicentric Castleman disease (iMCD). The site provides an overview of iMCD diagnostic criteria, practical steps for assessing lymph node biopsies, and links to additional resources for understanding CD/iMCD. Designed to enhance professional awareness and comprehension, thinkimcd.us aims to be a valuable tool for the medical community.
April 2024—Siemens Healthineers now offers the Anti-Müllerian Hormone assay to evaluate ovarian reserve. The assay runs on the Atellica IM analyzer and Advia Centaur immunoassay systems from serum and plasma samples. Results are available in about 28 minutes.
April 2024—Sebia announced it has received FDA 510(k) clearance for its free light chain kappa and lambda assays, intended to aid in diagnosing and monitoring patients who have multiple myeloma and immunoglobulin light chain amyloidosis. The assays quantify kappa or lambda free light chains in human serum using an enzyme-linked immunosorbent assay procedure. The kits are for in vitro diagnostic use only.
April 2024—StatLab Medical Products announced the acquisition of Poly Scientific R&D, a manufacturer and supplier of pathology stains, reagents, and paraffin for anatomic pathology laboratories. The acquisition includes Histology Control Systems, a division of Poly Scientific that manufactures and supplies tissue control slides.
March 2024—The Matrix Plus chemistry reference kit and standalone, ultra-high Matrix Plus level F for the calibration verification testing of creatinine assays by enzymatic and colorimetric methods are available from Verichem Laboratories. The ready-to-use reference materials offer constant protein content and pH across all concentration levels. The five-level Matrix Plus kit and level F feature a creatinine range from 0.2 mg/dL to 30.0 mg/dL and are intended to be treated as patient specimens. Shelf life and open-vial stability are 21 months from the manufacturing date.
March 2024—Bio-Rad Laboratories has published the third workbook in a P.A.C.E.-approved series designed to provide lab professionals with the training and education needed to maintain reliable test results. “Quality Control Process Optimization with Cost of Quality Application” focuses on a practical approach of cost of quality to the laboratory workflow process of quality control. After using the workbook, laboratorians will be able to construct a basis worksheet to calculate the failure costs of a selected failed laboratory process.
March 2024—Agilent Technologies announced an agreement with Incyte to develop companion diagnostics in hematology and oncology. The agreement enables Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development, global regulatory approvals, and commercialization to support clinical trials as well as the potential registration and commercialization of companion diagnostics in the United States and Europe.
March 2024—Innovative Lab Solutions announced the appointment of Bridget Ketron as its vice president of solutions. With a focus on enhancing efficiency, boosting cash collections, and ensuring compliance, Ketron will play a key role in driving the company’s growth and strategic partnerships.
March 2024—Avails Medical announced it has received FDA 510(k) clearance for its Equant system, an automated lab inoculation preparation system that consists of a single module instrument that holds a cuvette with an electrical sensor. It is intended for use with positive blood cultures samples for direct antimicrobial susceptibility testing without the traditional overnight subculture. The system works by preparing samples for direct susceptibility testing by manual agar disk diffusion.
